Sat, Nov 29, 2014, 12:22 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

symptoms88 158 posts  |  Last Activity: 15 hours ago Member since: May 24, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Shelf

    by symptoms88 15 hours ago
    symptoms88 symptoms88 15 hours ago Flag

    correction -"domestic corp" should read "domestic issuer".

  • symptoms88 by symptoms88 15 hours ago Flag

    First-It's not necessarily a non-issue. Even if the S3 is part of what you have to do upon becoming a domestic Corp., you do not have to file the prospectus, which is what they are about to also do. The prospectus defines how much can be publicly offered. That being said, this is easily could be happening as housekeeping for the future, or alternatively due to current interest shown by one or more institutions to buy a large amount of stock at At The Market (ATM) prices. I have seen that happen and once it becomes public for example that a respected biotech fund is the one buying, the stock price soars.

    Sentiment: Strong Buy

  • Reply to

    CEOs sale

    by symptoms88 Nov 27, 2014 8:36 AM
    symptoms88 symptoms88 Nov 27, 2014 8:55 AM Flag

    Actually, upon further review, this and the other recent director trades all appear to be 10b5-1 (ie; pre-scheduled and automatic) trades anyway.

  • symptoms88 by symptoms88 Nov 27, 2014 8:36 AM Flag

    by looking at the SEC form, he only had several weeks to exercise right to buy the options at $14.52. He may not have had the 9 million cash he needed to buy at that price, and thus was going to have a problem exercising the option to buy. Therefore he arranged to buy and sell them simultaneously, selling at $15.25 and netting 73 cents per share. He is pocketing well under a million dollars here. This could easily be done with a 2 day loan for the 9M or so that it cost to buy at $14.52. I am open to being corrected as I am totally unfamiliar if HR is a guy with huge bucks that could easily have laid out the 9M out of his own pocket and held.

    Sentiment: Strong Buy

  • symptoms88 symptoms88 Nov 22, 2014 8:21 AM Flag

    They said that about google. Brand and media is everything.

  • Reply to

    Just added more at $5.07

    by birdyvax Nov 21, 2014 10:34 AM
    symptoms88 symptoms88 Nov 21, 2014 11:30 AM Flag

    Agree. Having filled only 200sh of my PM 6k order at 5.04 i was fortunate to pick up 5800SH at $5 today. Now i have the nice round number of SH that i want. GLTA.

    Sentiment: Strong Buy

  • Reply to

    Baker Bros...

    by symptoms88 Nov 21, 2014 8:29 AM
    symptoms88 symptoms88 Nov 21, 2014 9:42 AM Flag

    could happen but this is a long term hold and I usually just buy if I like the price instead of counting the pennies. Anyway only 200sh of the 6k went

  • Reply to

    Baker Bros...

    by symptoms88 Nov 21, 2014 8:29 AM
    symptoms88 symptoms88 Nov 21, 2014 8:37 AM Flag

    Not to me. Just wasn't aware of it and if it was new the mkt would react. Anyway thats my bid to add 6k shares at 5.04, if anyone is interested in selling.

  • Reply to

    Question on options

    by prentisscharlie Nov 20, 2014 11:32 PM
    symptoms88 symptoms88 Nov 21, 2014 8:36 AM Flag

    yes if own 5$ calls or calls at lower strike price they or worthless. As for 2nd question the PPS will not always close below your strike price and their are multiple strike prices (there could be 30+ strike prices for some stocks, usually the big mkt cap stocks).

  • symptoms88 by symptoms88 Nov 21, 2014 8:29 AM Flag

    have over 1.2M NVAX shares. Is that old knowledge? Odd that I wasn't aware of that but doesn't look like a brand new position either...

  • symptoms88 symptoms88 Nov 20, 2014 9:42 AM Flag

    thanks all

  • symptoms88 symptoms88 Nov 20, 2014 9:22 AM Flag

    Can someone remind me when enrollment of RSV maternal had started? Thanks. More great news. I have never been more confident in the long term prospects of an investment...

    Sentiment: Strong Buy

  • Reply to

    Momentum Going Into MS Results

    by kaplan1975 Nov 18, 2014 2:01 PM
    symptoms88 symptoms88 Nov 20, 2014 7:41 AM Flag

    Abstract for MS came out like a year ago. They are not pursuing MS. This co has no known catalyst in any time frame, period. The only thing mildly interesting would be further TSO results for autism. Otherwise this is now a dermatology company, whatever that means. I am not a basher I lost quite a bit here betting on TSO.

  • Reply to

    Keeping the stock price down

    by emerginganalyst Nov 14, 2014 9:09 PM
    symptoms88 symptoms88 Nov 15, 2014 8:28 AM Flag

    Just a thought. The massive new shorting prevented the retail frenzy that would/should have accompanied the news. Now retail is left with the impression that even with the news this is a $2 stock. Now shorts can exit in an orderly manner. I have seen this before-namely shorts doubling down in order to get out shorty afterwards without trampling each other. The shorts now can exit without getting crushed, and the PPS would now rise in a more orderly manner. Just a thesis here. If its right though I think this will steadily rise at least a good 50% over the next 2 weeks or so.

  • Reply to

    Trevor (SA) is now long ...

    by drt42 Nov 14, 2014 5:24 PM
    symptoms88 symptoms88 Nov 14, 2014 5:40 PM Flag

    I read Trevors articles and they remind me of 1st grade essays. I'm long too but the guy has never said an original or insightful thing about the company. Sorry Trevor. Consider this post only "somewhat" critical of your writings.

  • symptoms88 by symptoms88 Nov 14, 2014 5:37 PM Flag

    so painfully obvious. He writes article about how important Avastin's approval based on PFS alone will be to
    Oxigene. Then, he gets the inside word that Avastin IS ACTUALLY ABOUT TO RECEIVE FDA APPROVAL. Immediatelly he writes an article to undermine the positive effect that Avastin approval will have on Oxigene. Do you think that if the word he got was that Avastin was going to be denied FDA approval he would have written the same article? Of course not. He realized he unwittingly had publicized a huge potential positive catalyst for OXGN, and he had to reverse himself when he realized it was actually going to happen. I don't know who he is beholden to or why, but it does not take a brain surgeon to figure out there are agendas behind his machinations.

  • Reply to

    When does JNJ just say...

    by symptoms88 Nov 13, 2014 7:21 AM
    symptoms88 symptoms88 Nov 14, 2014 8:06 AM Flag

    First time for everything. I don't think the co would be willing to sell itself today for $250.There has never been an ibrutinib before. Anyway, when the stock is $200/SH in 6 months or so, as some anyalysts already predict, then it would be about a 90% premium. Oh yeah, thats the premium GILD paid for Pharmasset. Not so asinine, but you are welcome to think so.

  • PCYC is just a monster with countless new combinations and indications that will come to fruition in the next several of years. Let's just buy the rest of this thing at this point for lets say 30 BILLION, knowing that over a 20 year horizon that will result in a huge return for our company, $375 is the right number to buy this thing. I know it sounds crazy but it just isn't. Hey JNJ, JUST DO IT!!!!

  • Reply to

    Fuerstein Article is...

    by symptoms88 Nov 12, 2014 7:15 AM
    symptoms88 symptoms88 Nov 12, 2014 7:37 AM Flag

    Lol. I feel good. As with almost all retail dominated stocks, Fuerstein has been anti-OXGN for a long time. He correctly nailed Avastin FDA approval as vital to OXGN. When he realized that Avastin actually will be approved, he needed to undo the catalyst that he himself helped publicize. He then writes a hit piece (which he disguises as objective). His logic in the article is perverse. Let it drop more today I am adding and adding.

    Sentiment: Strong Buy

  • symptoms88 by symptoms88 Nov 12, 2014 7:15 AM Flag

    way off base. BUT his confident prediction that Avastin will get FDA approval this month is fantastic. He sounds like he has the inside track on the Avastin approval issue. As for the rest of the article it relies on the false premise that a completely safe and non-toxic Fosbretabulin needs to show superior PFS to chemotherapy. The true fact is that if phase 3 shows similar results, namely a 52% (Avastin + chemo) versus 43% (Avastin + Fosbretabulin) improvement in PFS over Avastin alone, then OXGN is GOLDEN, because a large portion of the platinum resistant sick population would choose the Fosbretabulin alternative over chemotherapy. To that end, contrary to Fuerstein's article, there is no problem choosing what the "comparator arm" will be in phase 3. Rather it will be exactly the same as phase 2 (ie; Avastin + Fosbretabulin versus Avastin alone). If you then duplicate the 43% results in the phase 3 trial (for platinum resistant patients), you WILL GET (no doubt) FDA approval for Fosbretabulin, bc the FDA in NO WAY can approve AVASTIN based on PFS alone, but then deny a safe drug that adds 43% to that PFS. The only real issue becomes what confidence you have that Phase 3 can duplicate phase 2 for the subset of platinum resistant patients. There was no way you were going to get statistical significance in the subset of 27 subjects in the phase 2. It's just too small a sample. While there is no reason not to expect results in phase 3 consistent with phase 2, you just don't know for sure. But you never do. What we do know is that if you can duplicate the results in a bigger sample, you have a blockbuster drug that will be approved. With a relatively tiny market cap I would think OXGN is a great bet for a takeover or partnership, once Avastin is FDA approved in a couple of weeks.

    Sentiment: Strong Buy

NVAX
5.34-0.10(-1.84%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.